Novanta authorizes $200 million share repurchase program

Novanta Inc. (NASDAQ:NOVT) has authorized an additional $200 million for share repurchases, bringing its total capacity to $231 million, signaling board confidence in its financial strength and growth strategy. This initiative, aimed at maximizing shareholder value, is supported by the medical technology company's robust financials, including liquid assets exceeding short-term obligations and a recent Q2 2025 adjusted EPS of $0.76, which surpassed analyst expectations. Despite a 26% year-to-date stock decline, the company is reportedly trading near its fair value and intends to continue investing in organic growth and strategic acquisitions.

Analysis

Novanta Inc. (NOVT) has signaled strong confidence in its financial position and outlook by authorizing an additional $200 million for its share repurchase program, bringing the total capacity to $231 million. This capital return initiative is substantiated by robust underlying fundamentals, including a recent earnings beat for Q2 2025, where adjusted EPS of $0.76 surpassed analyst expectations of $0.73. The company's financial health is further evidenced by a strong liquidity position, with liquid assets exceeding short-term obligations and a current ratio of 2.54 on annual revenue of $956.88 million. Despite this positive operational performance and management confidence, the stock has experienced a significant 26% decline year-to-date. This divergence between fundamental strength and stock performance is notable, particularly as analysis cited in the report suggests the stock is trading near its fair value. The company plans to fund repurchases from cash on hand while continuing to prioritize investments in organic growth and strategic acquisitions, indicating a balanced capital allocation strategy.

Key Decisions for Investors

• The significant expansion of the share repurchase program, following a 26% year-to-date stock decline, may signal an attractive entry point for value-oriented investors, as management is actively supporting the stock at a price it deems undervalued.
• Investors should monitor the company's execution of its balanced capital allocation strategy, paying close attention to the pace of share buybacks and any announcements related to M&A, which are presented as primary drivers for future growth.
• Given the contrast between the stock's sharp YTD decline and the positive fundamental news, it is prudent to investigate potential industry-wide headwinds or company-specific risks that may not be fully reflected in the recent earnings beat before initiating or adding to a position.